Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Subscribe To Our Newsletter & Stay Updated
